Top Markets
#1 Black Phoenix Black Phoenix +354.75%
#2 Akedo Akedo +92.63%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +59.96%
#5 Acurast Acurast +37.34%
#6 OpenEden OpenEden +35.98%
#7 BasedHype BasedHype +27.14%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.45%
#9 Cryptopia Cryptopia +21.54%
#10 Avantis Avantis +20.43%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Immunotech Laboratories, Inc. Immunotech Laboratories, Inc.

Immunotech Laboratories, Inc.

IMMB
Rank in Stocks #40594
Immunotech Laboratories, Inc. develops and commercializes proprietary proteins... Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as a subsidiary of Enzolytics, Inc.
Share Price
$0.0002
Last synced: 2026-08-12
Market Cap
$114.99K
Change (1 day)
0.00%
Change (1 year)
100.00%
Country
US
Trade Immunotech Laboratories, Inc. (IMMB)

Category

Healthcare
P/E ratio for Immunotech Laboratories, Inc. (IMMB)
P/E ratio as of 2026 TTM: 0
According to Immunotech Laboratories, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Immunotech Laboratories, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.